At Ergomed, we don’t just understand rare disease research; we lead it.
As a specialized Clinical Research Organization (CRO) with a dedicated focus on rare diseases, Ergomed partners with biotech and pharma companies to drive innovation and bring much-needed therapies to underserved patient populations. With years of expertise managing complex trials, particularly for neuromuscular disorders, we are uniquely positioned to navigate the challenges these studies present, ensuring both scientific and operational excellence.

Unmatched Expertise in Rare Neuromuscular Disorders
Our experience speaks for itself. Ergomed has led successful trials for a spectrum of rare neuromuscular diseases—spanning from Duchenne Muscular Dystrophy to ALS and beyond—delivering impactful results across North America and Europe. With a solid history of conducting multi-country, late-stage studies, our specialized knowledge and close partnerships with Key Opinion Leaders (KOLs) ensure that every trial is built on the strongest foundation.
A Patient-Centric Approach That Drives Success
Our commitment extends beyond the science; we prioritize the patients. Led by Paula Orandash, Director of Patient Engagement, Ergomed’s approach is rooted in patient advocacy. We work closely with advocacy organizations, ensuring that patient and caregiver voices are heard, enhancing support throughout the clinical journey. For Ergomed, patient-centered trials are essential to advancing treatments that truly improve quality of life.